CoChat

The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer

Published version of a preprint

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

The gut microbiome (GM) plays an important role in shaping systemic immune responses and influences immune checkpoint inhibitor (ICI) efficacy. Antibiotics worsen clinical outcomes in patients receiving ICI. However, whether GM profiling and baseline antibiotic can be a biomarker of ICI efficacy in advanced non–small cell lung cancer (NSCLC) remains unknown. We prospectively collected baseline (pre-ICI) fecal samples and clinical data of 70 Japanese patients suffering from advanced NSCLC and treated them with anti–PD-1/PD-L1 antibodies as a first-line or treatment-refractory therapy. We performed 16S rRNA V3–V4 sequencing of gene amplicons of fecal samples, and bacteria diversity and differential abundance analysis was performed. The clinical endpoints were objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and immune-related adverse events (irAE). ORR was 34%, and median PFS and OS were 5.2 and 16.2 months, respectively. Patients who received pre-ICI antibiotic had lower alpha diversity at baseline and underrepresentation of Ruminococcaceae UCG 13 and Agathobacter. When analyzing antibiotic-free patients, alpha diversity correlated with OS. In addition, Ruminococcaceae UCG 13 and Agathobacter were enriched in patients with favorable ORR and PFS >6 months. Ruminococcaceae UCG 13 was enriched in patients with OS >12 months. GM differences were observed between patients who experienced low- versus high-grade irAE. We demonstrated the negative influence of antibiotic on the GM composition and identified the bacteria repertoire in patients experiencing favorable responses to ICI. See articles by Tomita et al., p. 1236, and Peng et al., p. 1251

Overview

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-20-0196

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. Batten, 2020, Gut microbiota predicts response and toxicity with neoadjuvant immunotherapy

Cited by

See all 340

Metadata

Authors
Hakozaki, T., Richard, C., Elkrief, A., Hosomi, Y., Benlaïfaoui, M., Mimpen, I., Terrisse, S., Derosa, L., Zitvogel, L., Routy, B., & Okuma, Y.
Affiliations
  • Tokyo Metropolitan Komagome Hospital (JP)
  • Université de Montréal (CA)
  • Jewish General Hospital (CA)
  • Inserm (FR)
Venue
Cancer Immunology Research
Published
2020-10-01
Volume
8
Issue
10
Pages
1243-1250
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W3044111226
Cited by
316
References
40
Citations by year
2026: 45 · 2025: 67 · 2024: 54 · 2023: 61 · 2022: 51 · 2021: 31 · 2020: 7
FWCI
13.91
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • JSPS KAKENHI (JP19K16820)
  • Ligue contre le Cancer
  • Agence Nationale de la Recherche
  • Association pour la recherche sur le cancer
  • Cancéropôle Ile-de-France
  • Fondation pour la Recherche Médicale
  • Institut National du Cancer
  • Inserm
  • the LabEx Immuno-Oncology
  • the RHU Torino Lumière (ANR-16-RHUS-0008)
  • the Seerave Foundation
  • the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination
  • RHU Torino Lumière (ANR-16-RHUS-0008)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
gut microbiota, immune checkpoint inhibitors, non-small cell lung cancer, PD-1/PD-L1 blockade, antibiotic exposure, Agathobacter, gut microbiota diversity, immune-related adverse events, predictive biomarkers, treatment response, overall survival
MeSH terms
Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Prospective Studies, Survival Analysis, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/2326-6066.cir-20-0196
The paper
Hakozaki, T., Richard, C., Elkrief, A., Hosomi, Y., Benlaïfaoui, M., Mimpen, I., Terrisse, S., Derosa, L., Zitvogel, L., Routy, B., & Okuma, Y. (2020). The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-20-0196

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.